Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Department of Geriatrics and Orthopedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; UOC Geriatria, Disturbi Cognitivi e Demenze, Dipartimento di Cure Primarie, AUSL Modena, 41121 Modena, Italy.
Arch Gerontol Geriatr. 2025 Jan;128:105636. doi: 10.1016/j.archger.2024.105636. Epub 2024 Sep 11.
There is a need to balance the benefits and risks associated with strong anticholinergic medications in older adults, particularly among those with frailty and cognitive impairment. This study explored the international prevalence of strong anticholinergic medication use in residents of nursing homes with and without cognitive impairment and frailty.
Secondary, cross-sectional analyses of data from 5,800 residents of 106 nursing homes in Australia, China, Czech Republic, England, Finland, France, Germany, Israel, Italy, Japan, Netherlands, and Spain were conducted. Strong anticholinergic medications were defined as medications with a score of 2 or 3 on the Anticholinergic Cognitive Burden scale. Dementia or cognitive impairment was defined as a documented diagnosis or using a validated scale. Frailty was defined using the FRAIL-NH scale as 0-2 (non-frail), 3-6 (frail) and 7-14 (most-frail). Data were analyzed using descriptive statistics.
Overall, 17.4 % (n = 1010) residents used ≥1 strong anticholinergic medication, ranging from 1.3 % (n = 2) in China to 27.1 % (n = 147) in Italy. The most prevalent strong anticholinergics were quetiapine (n = 290, 5.0 % of all residents), olanzapine (132, 2.3 %), carbamazepine (102, 1.8 %), paroxetine (88, 1.5 %) and amitriptyline (87, 1.5 %). Prevalence was higher among residents with cognitive impairment (n = 602, 17.9 %) compared to those without (n = 408, 16.8 %), and among residents who were most frail (n = 553, 17.9 %) compared to those who were frail (n = 286, 16.5 %) or non-frail (n = 171, 17.5 %).
One in six residents who were most frail and living with cognitive impairment used a strong anticholinergic. However, there was a 20-fold variation in prevalence across the 12 countries. Targeted deprescribing interventions may reduce potentially avoidable medication-harm.
需要权衡与老年人使用强效抗胆碱能药物相关的益处和风险,尤其是在体弱和认知障碍患者中。本研究旨在探讨患有和不患有认知障碍和衰弱的养老院居民中使用强效抗胆碱能药物的国际流行率。
对来自澳大利亚、中国、捷克共和国、英格兰、芬兰、法国、德国、以色列、意大利、日本、荷兰和西班牙的 106 家养老院的 5800 名居民进行了二次横断面数据分析。将抗胆碱能认知负担量表评分为 2 或 3 的药物定义为强效抗胆碱能药物。痴呆或认知障碍定义为有记录的诊断或使用经过验证的量表。衰弱使用 FRAIL-NH 量表定义为 0-2(非衰弱)、3-6(衰弱)和 7-14(最衰弱)。使用描述性统计分析数据。
总体而言,17.4%(n = 1010)的居民使用了≥1 种强效抗胆碱能药物,范围从中国的 1.3%(n = 2)到意大利的 27.1%(n = 147)。最常见的强效抗胆碱能药物为喹硫平(n = 290,占所有居民的 5.0%)、奥氮平(n = 132,2.3%)、卡马西平(n = 102,1.8%)、帕罗西汀(n = 88,1.5%)和阿米替林(n = 87,1.5%)。与无认知障碍的居民(n = 408,16.8%)相比,有认知障碍的居民(n = 602,17.9%)的患病率更高,与虚弱的居民(n = 286,16.5%)相比,最虚弱的居民(n = 553,17.9%)的患病率更高。
最虚弱且患有认知障碍的居民中,每 6 人就有 1 人使用了强效抗胆碱能药物。然而,12 个国家的患病率差异高达 20 倍。有针对性的药物减量干预措施可能会减少潜在的药物伤害。